IP Library Granted Patent US 8,257,957
Granted Patent B2
US 8,257,957 · App. 12/439,812 · Granted Sep 4, 2012

Production of isoprenoids and isoprenoid precursors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,257,957
App. No.
12/439,812
Granted
Sep 4, 2012
Kind
B2
Abstract

The present invention provides genetically modified host cells and use of same for producing isoprenoid compounds.

Claims (37)

1. A host cell capable of producing an isoprenoid and comprising:

a coding region encoding a mevalonate kinase (MK);

a nucleic acid comprising a nucleotide sequence encoding one or more mevalonate pathway enzyme other than mevalonate kinase selected from a phosphomevalonate kinase (PMK), and a mevalonate pyrophosphate decarboxylase (MPD); and

a heterologous nucleotide sequence encoding a terpene synthase;

wherein the level of MK produced in said host cell is at least 50% higher than the level of at least one of PMK and MPD.

2. A host cell according to claim 1 , wherein the MK coding region is under the control of a first promoter and the nucleotide sequence encoding one or more mevalonate pathway enzyme other than mevalonate kinase is under the control of a second promoter wherein the second promoter is weaker than the first promoter.

3. A host cell according to claim 2 , wherein the first promoter is a constitutively active promoter.

4. A host cell according to claim 2 , wherein the first promoter is an inducible promoter.

5. A host cell according to claim 2 , wherein the first promoter is stronger than a native Escherichia coli Lac promoter or a PLac promoter.

6. A host cell according to claim 2 , wherein the first promoter is a lacUV5 promoter or a trc promoter.

7. A host cell according to claim 1 , wherein said cell comprises at least two coding regions comprising nucleotide sequences encoding a mevalonate kinase.

8. A host cell according to claim 7 , wherein the copy number of coding regions comprising nucleotide sequences encoding a mevalonate kinase is higher than the copy number of coding regions encoding one or more mevalonate pathway enzymes other than mevalonate kinase.

9. A host cell according to claim 1 , further comprising a nucleotide sequence encoding an isopentenyl pyrophosphate (IPP) isomerase.

10. A host cell according to claim 1 , further comprising a heterologous nucleic acid comprising a nucleotide sequence encoding a prenyltransferase selected from a farnesyl diphosphate synthase, a geranyl diphosphate synthase, and a geranylgeranyl diphosphate synthase.

11. A host cell according to claim 1 , wherein the isoprenoid is a diterpene, a triterpene, or a sesquiterpene.

12. A host cell according to claim 1 , wherein one or more of the nucleotide sequences encoding the mevalonate kinase or mevalonate pathway enzymes is codon-optimized for expression in said host cell.

13. A host cell according to claim 1 , wherein the terpene synthase is selected from an amorpha-4,11-diene synthase; a beta-caryophyllene synthase; a germacrene A synthase; a 8-epicedrol synthase; a valencene synthase; a (+)-delta-cadinene synthase; a germacrene C synthase; a (E)-beta- farnesene synthase; a casbene synthase; a vetispiradiene synthase; a 5-epi-aristolochene synthase; an aristolchene synthase alpha-humulene synthase; an (E,E)-alpha-farnesene synthase; a (−)-beta-pinene synthase; a gamma-terpinene synthase; a limonene cyclase; a linalool synthase; a 1,8-cineole synthase; a (+)-sabinene synthase; an E-alpha-bisabolene synthase; a (+)-bornyl diphosphate synthase; a levopimaradiene synthase; an abietadiene synthase; an isopimaradiene synthase; a (E)-gamma-bisabolene synthase; a taxadiene synthase; a copalyl pyrophosphate synthase; a kaurene synthase; a longifolene synthase; a gamma-humulene synthase; a Delta-selinene synthase; a beta-phellandrene synthase; a limonene synthase; a myrcene synthase; a terpinolene synthase; a (−)-camphene synthase; a (+)-3-carene synthase; a syn-copalyl diphosphate synthase; an alpha-terpineol synthase; a syn-pimara-7,15-diene synthase; an ent-sandaaracopimaradiene synthase; a stemer-13-ene synthase; a E-beta-ocimene; a S-linalool synthase; a geraniol synthase; a gamma-terpinene synthase; a linalool synthasel; a E-beta-ocimene synthase; an epi-cedrol synthase; an alpha-zingiberene synthase; a guaiadiene synthase; a cascarilladiene synthase; a cis-muuroladiene synthase; an aphidicolan-16b-ol synthase; an elizabethatriene synthase; a sandalol synthase; a patchoulol synthase; a zinzanol synthase; a cedrol synthase; a scareol synthase, copalol synthase; and a manool synthase.

14. A host cell according to claim 1 , wherein the host cell is a prokaryotic cell.

15. A host cell according to claim 1 , wherein the host cell is a eukaryotic cell.

16. An Escherichia coli host cell capable of producing an isoprenoid and comprising:

a first expression plasmid comprising a nucleotide sequence encoding a mevalonate kinase;

a second expression plasmid comprising a nucleotide sequence encoding one or more mevalonate pathway enzymes other than mevalonate kinase, wherein the copy number of the second expression plasmid is lower than that of the first expression plasmid; and

a heterologous nucleotide sequence encoding a terpene synthase.

17. A host cell according to claim 14 , wherein the host cell is a prokaryotic cell that does not synthesize an isopentenyl pyrophosphate (IPP) via an endogenous mevalonate pathway.

18. A host cell according to claim 1 , wherein the host cell is genetically modified with one or more nucleic acids comprising nucleotide sequences encoding one or more of:

a) an acetoacetyl-CoA thiolase;

b) an enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form hydroxymethylglutaryl- CoenzymeA (HMG-CoA); and

c) an enzyme that converts HMG-CoA to mevalonate.

19. A host cell according to claim 18 , wherein the enzyme that condenses acetoacetyl-CoA with acetyl-CoA to form HMG-CoA is HMG-CoA synthase.

20. A host cell according to claim 16 , wherein the mevalonate pathway enzymes other than mevalonate kinase are selected from a phosphomevalonate kinase (PMK), and a mevalonate pyrophosphate decarboxylase (MPD).

21. A host cell according to claim 16 , further comprising a nucleotide sequence encoding an isopentenyl pyrophosphate (IPP) isomerase.

22. A host cell according to claim 16 , further comprising a heterologous nucleic acid comprising a nucleotide sequence encoding a prenyltransferase selected from a farnesyl diphosphate synthase, a geranyl diphosphate synthase, and a geranylgeranyl diphosphate synthase.

23. A host cell according to claim 16 , wherein the isoprenoid is a diterpene, a triterpene, or a sesquiterpene.

24. A host cell according to claim 16 , wherein one or more of the nucleotide sequences encoding the mevalonate kinase or mevalonate pathway enzymes is codon-optimized for expression in said host cell.

25. A host cell according to claim 16 , wherein the terpene synthase is selected from an amorpha-4,11-diene synthase; a beta-caryophyllene synthase; a germacrene A synthase; a 8-epicedrol synthase; a valencene synthase; a (+)-delta-cadinene synthase; a germacrene C synthase; a (E)-beta- farnesene synthase; a casbene synthase; a vetispiradiene synthase; a 5-epi-aristolochene synthase; an aristolchene synthase alpha-humulene synthase; an (E,E)-alpha-farnesene synthase; a (−)-beta-pinene synthase; a gamma-terpinene synthase; a limonene cyclase; a linalool synthase; a 1,8-cineole synthase; a (+)-sabinene synthase; an E-alpha-bisabolene synthase; a (+)-bornyl diphosphate synthase; a levopimaradiene synthase; an abietadiene synthase; an isopimaradiene synthase; a (E)-gamma-bisabolene synthase; a taxadiene synthase; a copalyl pyrophosphate synthase; a kaurene synthase; a longifolene synthase; a gamma-humulene synthase; a Delta-selinene synthase; a beta-phellandrene synthase; a limonene synthase; a myrcene synthase; a terpinolene synthase; a (−)-camphene synthase; a (+)-3-carene synthase; a syn-copalyl diphosphate synthase; an alpha-terpineol synthase; a syn-pimara-7,15-diene synthase; an ent-sandaaracopimaradiene synthase; a stemer-13-ene synthase; a E-beta-ocimene; a S-linalool synthase; a geraniol synthase; a gamma-terpinene synthase; a linalool synthasel; a E-beta-ocimene synthase; an epi-cedrol synthase; an alpha-zingiberene synthase; a guaiadiene synthase; a cascarilladiene synthase; a cis-muuroladiene synthase; an aphidicolan-16b-ol synthase; an elizabethatriene synthase; a sandalol synthase; a patchoulol synthase; a zinzanol synthase; a cedrol synthase; a scareol synthase, copalol synthase; and a manool synthase.

26. A host cell according to claim 16 , wherein the level of MK produced in said host cell is at least 50% higher than the level of at least one of the mevalonate pathway enzymes other than mevalonate kinase.

27. A host cell according to claim 18 , wherein the enzyme that converts HMG-CoA to mevalonate is HMG-CoA reductase.

Assignments (19)
SECURITY INTEREST Recorded May 24, 2024
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 067528/0467 →
SECURITY INTEREST Recorded Aug 17, 2023
From: AMYRIS, INC.; AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; APRINNOVA, LLC; AMYRIS-OLINKA, LLC; ONDA BEAUTY INC.; UPLAND 1 LLC; AMYRIS ECO-FAB LLC; CLEAN BEAUTY 4U HOLDINGS, LLC; AMYRIS CLEAN BEAUTY LATAM LTDA; INTERFACES INDUSTRIA E COMERCIA DE COSMETICOS LTDA; AMYRIS BIOTECHNOLOGIA DO BRASIL LTDA; AMYRIS EUROPE TRADING B.V. (NETHERLANDS); AMYRIS BIO PRODCUTS PORTUGAL, UNIPESSOAL, LDA; BEAUTY LABS INTERNATIONAL LIMITED; AMYRIS UK TRADING LIMITED
To: EUAGORE, LLC
Reel/Frame 064619/0778 →
SECURITY INTEREST Recorded Aug 3, 2023
From: AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; AMYRIS, INC.
To: MUIRISC, LLC
Reel/Frame 064492/0518 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2023
From: NAXYRIS S.A.
To: AMYRIS, INC.
Reel/Frame 062310/0378 →
CHANGE OF NAME Recorded Nov 14, 2022
From: AMYRIS BIOTECHNOLOGIES, INC.
To: AMYRIS, INC.
Reel/Frame 061935/0461 →
SECURITY INTEREST Recorded Oct 18, 2022
From: AMYRIS, INC.
To: FORIS VENTURES, LLC
Reel/Frame 061703/0499 →
SECURITY INTEREST Recorded Nov 21, 2019
From: AMYRIS, INC.
To: NAXYRIS S.A.
Reel/Frame 051081/0729 →
RELEASE OF SECURITY INTEREST Recorded Aug 28, 2019
From: STEGODON CORPORATION
To: AMYRIS, INC.
Reel/Frame 050206/0606 →
SECURITY INTEREST Recorded Aug 16, 2019
From: AMYRIS, INC.
To: NAXYRIS S.A.
Reel/Frame 050081/0106 →
SECURITY INTEREST Recorded Jun 16, 2016
From: HERCULES CAPITAL INC.
To: STEGODON CORPORATION
Reel/Frame 039048/0251 →
SECURITY INTEREST Recorded Jun 3, 2016
From: AMYRIS, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 038878/0381 →
RELEASE OF SECURITY INTEREST Recorded Mar 31, 2014
From: MAXWELL (MAURITIUS) PTE LTD
To: AMYRIS, INC.
Reel/Frame 032578/0357 →
RELEASE OF SECURITY INTEREST Recorded Mar 28, 2014
From: TOTAL ENERGIES NOUVELLES ACTIVITES USA, SAS (F/K/A TOTAL GAS & POWER USA, SAS)
To: AMYRIS, INC.
Reel/Frame 032554/0001 →
RELEASE OF SECURITY INTEREST Recorded Mar 27, 2014
From: TOTAL ENERGIES NOUVELLES ACTIVITIES USA, SAS (F/K/A TOTAL GAS & POWER USA, SAS)
To: AMYRIS, INC.
Reel/Frame 032551/0828 →
SECURITY AGREEMENT Recorded Nov 8, 2013
From: AMYRIS, INC.
To: TOTAL ENERGIES NOUVELLES ACTIVITES USA
Reel/Frame 031607/0314 →
SECURITY AGREEMENT Recorded Oct 23, 2013
From: AMYRIS, INC.
To: MAXWELL (MAURITIUS) PTE LTD
Reel/Frame 031478/0933 →
SECURITY AGREEMENT Recorded May 9, 2013
From: AMYRIS, INC.
To: TOTAL GAS & POWER USA, SAS
Reel/Frame 030389/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2009
From: KEASLING, JAY D.; NOWROOZI, FARNAZ F.; PITERA, DOUGLAS J.; ANTHONY, JENNIFER
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 023650/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2009
From: NEWMAN, JACK D.; ANTHONY, LARRY
To: AMYRIS BIOTECHNOLOGIES, INC.
Reel/Frame 023651/0520 →